单细胞测序揭示复发多发性骨髓瘤耐药通路与治疗靶点
本研究为前瞻性多中心单臂临床试验(NCT04065789),联合纵向单细胞RNA测序,纳入41例对含硼替佐米诱导方案无效或早期复发的初诊多发性骨髓瘤患者,评估达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合方案的安全性(主要终点)与疗效。治疗安全且耐受良好,获得深度持久缓解;探索性分析揭示缺氧耐受、蛋白折叠和线粒体呼吸等耐药通路,并将PPIA确定为潜在治疗靶点。
要点
- 达雷妥尤单抗联合卡非佐米、来那度胺和地塞米松在难治/早期复发MM中安全耐受且深度持久缓解。
- 单细胞测序揭示耐药MM的缺氧耐受、蛋白折叠和线粒体呼吸等分子通路。
- PPIA是耐药MM潜在靶点,敲除或抑制可增敏蛋白酶体抑制剂。
核心结论
- 在含硼替佐米诱导失败或早期复发的初诊MM患者中,达雷妥尤单抗联合卡非佐米、来那度胺和地塞米松安全耐受并获深度持久缓解。
- 单细胞RNA测序揭示耐药MM的缺氧耐受、蛋白折叠和线粒体呼吸通路,PPIA为潜在治疗靶点。
研究设计与样本
- 前瞻性、多中心、单臂临床试验(NCT04065789),联合纵向单细胞RNA测序。
- 纳入41例对含硼替佐米诱导方案无效或早期复发的初诊MM患者,主要终点为安全性和耐受性。
- 探索性分析比较41例原发难治和早期复发患者与11例健康受试者及15例初诊MM患者。
主要发现
- 治疗安全且耐受良好,获得深度和持久缓解。
- 比较分析揭示缺氧耐受、蛋白折叠和线粒体呼吸等新的MM耐药分子通路,并在CoMMpass较大临床队列中可推广。
- PPIA为蛋白折叠反应通路的核心酶,被确定为耐药MM的潜在新靶点。
- CRISPR-Cas9敲除PPIA或用小分子抑制剂环孢素抑制PPIA,可显著增敏MM肿瘤细胞对蛋白酶体抑制剂的反应。
临床怎么用
- 达雷妥尤单抗联合卡非佐米、来那度胺和地塞米松可作为含硼替佐米诱导失败或早期复发MM患者的治疗选择。
- PPIA可作为耐药MM的潜在治疗靶点,值得进一步临床转化研究。
局限性
- 研究为单臂设计,样本量有限,探索性分析结果需更大规模临床队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by clonal proliferation of malignant plasma cells. Despite extensive research, disease heterogeneity within and between treatment-resistant patients is poorly characterized. In the present study, we conduct a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) to study the molecular dynamics of MM resistance mechanisms. Newly diagnosed MM patients (41), who either failed to respond or experienced early relapse after a bortezomib-containing induction regimen, were enrolled to evaluate the safety and efficacy of a daratumumab, carfilzomib, lenalidomide and dexamethasone combination. The primary clinical endpoint was safety and tolerability. Secondary endpoints included overall response rate, progression-free survival and overall survival. Treatment was safe and well tolerated; deep and durable responses were achieved. In prespecified exploratory analyses, comparison of 41 primary refractory and early relapsed patients, with 11 healthy subjects and 15 newly diagnosed MM patients, revealed new MM molecular pathways of resistance, including hypoxia tolerance, protein folding and mitochondria respiration, which generalized to larger clinical cohorts (CoMMpass). We found peptidylprolyl isomerase A (PPIA), a central enzyme in the protein-folding response pathway, as a potential new target for resistant MM. CRISPR-Cas9 deletion of PPIA or inhibition of PPIA with a small molecule inhibitor (ciclosporin) significantly sensitizes MM tumor cells to proteasome inhibitors. Together, our study defines a roadmap for integrating scRNA-seq in clinical trials, identifies a signature of highly resistant MM patients and discovers PPIA as a potent therapeutic target for these tumors.
引用
- Cohen YC, Zada M, Wang SY, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021. PMID: 33619369. doi:10.1038/s41591-021-01232-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。